Table 1.

Baseline characteristicsa

CharacteristicSevelamer (n = 33)Calcium (n = 35)P
Gender (M/F; n [%])22/11 (67/33)18/17 (51/49)0.23
Race>0.99
    white32 (97)34 (97)
    black1 (3)1 (3)
Age (yr; mean ± SD)55.5 ± 15.453.9 ± 13.70.53
Menopausal status (n [%])0.0097
    premenopausal0 (0)8 (47)
    postmenopausal11 (100)9 (53)
BMI (kg/m2; mean ± SD)23.5 ± 3.525.3 ± 3.80.09
Smoker (n [%])8 (24)3 (9)0.10
Diabetes (n [%])2 (6)8 (23)0.08
Hypertension (n [%])24 (73)25 (71)>0.99
Primary cause of stage 5 CKD (n [%])0.18
    hypertension2 (6.1)6 (17.1)
    glomerulonephritis8 (24.2)7 (20.0)
    diabetes2 (6.1)7 (20.0)
    pyelonephritis3 (9.1)3 (8.6)
    polycystic kidneys3 (9.1)2 (5.7)
    interstitial nephrosis4 (12.1)0 (0)
    other11 (33.3)10 (28.6)
Dialysis vintage (mo; median [range])23 (4 to 222)25 (2 to 181)0.49
Phosphate binder use (in 30 d before screening; n [%])33 (100)35 (100)0.07
    calcium carbonate31 (94)32 (91)
    sevelamer1 (3)1 (3)
    calcium carbonate + sevelamer1 (3)0 (0)
    calcium carbonate + aluminum0 (0)2 (6)
Vitamin D use (in 12 mo before screening; n [%])22 (67)24 (69)1.0
  • a BMI, body mass index.